Daré Bioscience rises as Bayer exits Ovaprene partnership deal

Shares of women's health firm Daré Bioscience DARE.O rise 6% to $1.91 premarket

Co says it will regain full rights to its experimental contraceptive ovaprene after Bayer HealthCare decided to end its partnership with the U.S. biotech firm

The move gives Daré control over ovaprene as it enters late-stage testing, offering more flexibility on commercialization - co

Daré CEO Sabrina Martucci Johnson says recent trial results showed ovaprene was safe and well tolerated, with pregnancy rates matching expectations

Co expects to finish enrolling patients in its ongoing late-stage trial next year; study funded by grants including Gates Foundation

Including session's move, stock down ~41% YTD